Tag: relapsing-remitting
Pioneering proposal for a new framework to describe types of MS
Moving away from traditional clinical categories of MS may lead to better, and more personalised treatments for MS.
Cladribine approved in US for people with active secondary progressive MS
FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS
Disappointing results from CCSVI treatment trial
Chronic Cerebrospinal Venous Insufficiency (CCSVI) describes a potential reduction in blood flow in the major veins that drain blood from the brain and spinal cord over a prolonged period.
First treatment licensed for primary progressive MS in the US
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US